865186-94-3

Basic information

• Product Name: 3-CHLORO-5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)PYRIDINE
• Synonyms: 3-CHLORO-5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)PYRIDINE;3-CHLOROPYRIDINE-5-BORONIC ACID PINACOL ESTER;5-CHLOROPYRIDINE-3-BORONIC ACID, PINACOL ESTER;5-Chloropyridine-3-boronic acid pinacol ester, 90+%
• CAS NO: 865186-94-3
• Molecular Formula: C11H15BClNO2
• Molecular Weight: 239.51
• Mol File: 865186-94-3.mol
• Article Data: 7

Chemical Properties

• Melting Point: 79-81℃
• Boiling Point: 327.5 °C at 760 mmHg
• Flash Point: 151.9 °C
• Appearance: /
• Density: 1.14 g/cm³
• Vapor Pressure: 0.000384mmHg at 25°C
• Refractive Index: 1.505
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 3-CHLORO-5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)PYRIDINE(865186-94-3)
• EPA Substance Registry System: 3-CHLORO-5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)PYRIDINE(865186-94-3)

Safety Data

• Hazardous Substances Data: 865186-94-3(Hazardous Substances Data)

Usage

General Description

3-Chloro-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyridine is a chemical compound with the molecular formula C13H17BClN2O2. It is a pyridine derivative that contains a boron atom and a chlorine substituent. This chemical is commonly used in organic synthesis and medicinal chemistry as a reagent or building block for the synthesis of various biologically active compounds. The presence of a boron-containing group makes it an important reagent in Suzuki-Miyaura cross-coupling reactions, which are widely used in the synthesis of complex organic molecules. It is also used in the development of pharmaceuticals and agrochemicals due to its ability to modulate biological activities. Overall, 3-chloro-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyridine is a versatile and important chemical reagent in the field of organic and medicinal chemistry.

InChI:InChI=1/C11H15BClNO2/c1-10(2)11(3,4)16-12(15-10)8-5-9(13)7-14-6-8/h5-7H,1-4H3

Upstream product

• 626-60-8 3-Chloropyridine 
• 73183-34-3 bis(pinacol)diborane 
• 73583-39-8 3-bromo-5-chloropyridine 

Downstream Products

• 22353-33-9 3-chloro-5-nitropyridine 

Relevant articles and documents

Nitrogen-containing heterocyclic derivative and organic electroluminescent device thereof

The invention provides a nitrogen-containing heterocyclic derivative and an organic electroluminescent device thereof, and belongs to the technical field of organic electroluminescence. The nitrogen-containing heterocyclic derivative has strong hole block

meta-Nitration of Arenes Bearing ortho/para Directing Group(s) Using C?H Borylation

Herein, we report the meta-nitration of arenes bearing ortho/para directing group(s) using the iridium-catalyzed C?H borylation reaction followed by a newly developed copper(II)-catalyzed transformation of the crude aryl pinacol boronate esters into the corresponding nitroarenes in a one-pot fashion. This protocol allows the synthesis of meta-nitrated arenes that are tedious to prepare or require multistep synthesis using the existing methods. The reaction tolerates a wide array of ortho/para-directing groups, such as ?F, ?Cl, ?Br, ?CH3, ?Et, ?iPr ?OCH3, and ?OCF3. It also provides regioselective access to the nitro derivatives of π-electron-deficient heterocycles, such as pyridine and quinoline derivatives. The application of this method is demonstrated in the late-stage modification of complex molecules and also in the gram-scale preparation of an intermediate en route to the FDA-approved drug Nilotinib. Finally, we have shown that the nitro product obtained by this strategy can also be directly converted to the aniline or hindered amine through Baran's amination protocol.

WNT PATHWAY MODULATORS

The present invention relates to dihydropyrazolo[l,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.